Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-JIA: Maintenance versus tapering of TNF inhibitor monotherapy in juvenile idiopathic arthritis with sustained inactive disease
2026-525611-13-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of golimumab, etanercept and adalimumab in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Proportion of participants with disease flare at 12 months. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2026-525611-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525611-13-00.